Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Feb 23;129(8):1039-1041.
doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28.

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR

Elise A Chong  1 , J Joseph Melenhorst  2 , Simon F Lacey  2 , David E Ambrose  2 , Vanessa Gonzalez  2 , Bruce L Levine  2 , Carl H June  2 , Stephen J Schuster  1
Affiliations
Case Reports

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR

Elise A Chong et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PD-L1 immunhistochemistry and CT scans demonstrating clinical response to therapy. (A) PD-L1 (CD274) expression by the patient’s DLBCL cells. Biopsy was obtained prior to CART19 cell infusion. Immunohistochemical staining with an anti-PD-L1 antibody from Cell Signaling (clone E1J2J, catalog number 15165BF). The main image is at ×40 magnification; the upper-right corner inset at ×100. Microscope: Leica DM 2500, lens ×10. Camera: Leica, MC 170 HD. Acquisition software: LAS V4.8. (B) CT imaging on day of pembrolizumab infusion (day 26) and 3 weeks after pembrolizumab infusion (day 45).
Figure 2.
Figure 2.
Correlative studies examining changes in T-cell subsets and T-cell clones in relation to CART19 cell infusion and pembrolizumab infusion. (A) Percentage of CART19+CD3+ cells in peripheral blood. Percentage of CART19+ of CD3+ cells prior to CART19 infusion (pre), 3 days after CART19 infusion (day 3), 7 days after CART19 (day 7), 10 days after CART19 (day 10), 14 days after CART19 (day 14), 26 days after CART19 and 1 hour after pembrolizumab infusion (day 26), 27 days after CART19 and 1 day after pembrolizumab (day 27), 28 days after CART19 and 2 days after pembrolizumab (day 28), and 45 days after CART19 and 14 days after pembrolizumab (day 45). (B) Fold change from baseline in IL-6 serum levels. (C) Percentage of PD1+CD4+ cells and PD1+Eomes+CD4+ cells in peripheral blood. (D) Percentage of PD1+CD4+CART19+ cells and PD1+Eomes+CD4+CART19+ cells in peripheral blood. (E) Percentage of PD1+CD8+ cells and PD1+Eomes+C8+ cells in peripheral blood. (F) Percentage of PD1+CD8+CART19+ cells and PD1+Eomes+CD8+CART19+ cells in peripheral blood. (G) Changes in T-cell clones as determined by TCRβ deep sequencing (Adaptive Biotechnologies, immunoSEQ).
See this image and copyright information in PMC

References

    1. Topalian SL, Hodi FS, Brahmer JR, et al. . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. - PMC - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQM, et al. . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. - PMC - PubMed
    1. Hamid O, Robert C, Daud A, et al. . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144. - PMC - PubMed
    1. Wolchok JD, Kluger H, Callahan MK, et al. . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133. - PMC - PubMed
    1. Topalian SL, Sznol M, McDermott DF, et al. . Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030. - PMC - PubMed

MeSH terms

Substances